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 • Aldehyde dehydrogenases (ALDH) are enzymes that catalyse the oxidation of aldehydes to their 
consequent acids by a NAD(P)+-dependent irreversible reaction 
• This enzyme oxidises and detoxifies aldehydes that can be harmful to the organism 
• ALDH is considered a marker for CSCs, identifiable by the Aldefluor assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CANCER STEM CELLS (CSCs)... 
• Are a small tumour cell subpopulation that can initiate and drive tumourigenic growth 
• Carry out an asymmetric division: they are able to renew themselves and they can also differentiate 
•  Can arise from mutations in normal stem cells, progenitor or mature differentiated cells 
• Are responsible for therapy failure, recurrence and metastasis 
• Give another perspective in the treatment against cancer  Aldehyde dehydrogenase as a candidate target 
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1. CANCER STEM CELLS AND THEIR ORIGIN 2. ALDEHYDE DEHYDROGENASE 
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1. CSCs open new frontiers in the treatment against cancer 
2. ALDH is a good marker for CSCs because its identification and isolation is easier thanks to the Aldefluor Assay 
3. Resistance to conventional therapies and metastasis can be explained by CSCs, where ALDH plays a valuable 
role on this matter 
4. ATRA could be a novel cancer therapy by producing retinoic acid and causing differentiation, although non-
CSCs also have to be eliminated to eradicate all the bulk of the tumour by conventional therapies 
 
 
5. CONCLUSIONS 
Therapy 
failure 
(resistance) 
• Chemotherapy 
• Cooperation between 
ALDH and multi-drug 
resistance mechanism 
• Oxidation and 
inactivation of 
chemotherapeutic agents 
(cyclophosphamide) 
• Radiotherapy 
Metastasis 
• ALDH+ cells have 
demonstrated metastasic 
potential 
• This role may be due to the 
ALDH1A3 isoform 
ALDH is a CSC 
marker 
correlated with 
3. RETINOIC ACID SIGNALLING PATHWAY 4. THERAPIES THAT TARGET CSCs 
The interest of finding a CSC 
target is focused on the retinoic 
acid signalling pathway, in which 
ALDH plays an essential role. 
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Targeting CSC-
dependent of 
signalling pathways 
Some specific 
signalling pathways 
(TGF-β, Wnt, Notch 
and Hedgehog) are 
involved in the 
maintenance of the 
cancer stem cell 
state  
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inhibitor of Wnt 
signalling that 
ďloĐkades the β-
catenin-CREB 
binding protein 
interaction   proliferation 
Targeting the tumour 
microenvironment 
Affecting the 
microenvironment 
of the tumour, the 
maintenance of the 
stem cell state is lost 
and the EMT 
programme is 
altered 
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This therapy induces 
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All-trans retinoic 
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treatment inhibits 
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activating retinoic 
acid pathway 
Retinol (vitamin A) Retinaldehyde Retinoic acid 
(RA) 
Figure was produced using Servier Medical Art (www.servier.com) 
 
M 
E 
T 
H 
O 
D 
 
 
S 
T 
R 
A 
T 
E 
G 
Y 
 
 
 
E 
X 
A 
M 
P 
L 
E 
S 
Figure 2 | Aldefluor Assay. BODIPY-
aminoacetaldehyde can diffuse into the 
cell to be converted to a negatively-
charged fluorescent product named 
BODIPY-aminoacetate. 
Figure 3 | Synthesis, degradation and mode of 
action of retinoic acid. Retinol is oxidised to 
retinaldehyde by a reversible reaction given by 
alcohol dehydrogenase (ADH). Then, retinaldehyde 
is oxidised to RA by ALDH in the cytosol, and free 
RA goes into the nucleus attached to a chaperone 
protein(CRABP2 or FABP5) in order to bind to RAR 
or RXR. When RA binds to the heterodimer, histone 
acetylation and activation of transcription is given. 
This signalling pathway is stopped when the 
degradation of RA is given by CYP26 enzymes. 
Figure 1 | Origin of cancer stem cells. CSCs can renew themselves to preserve the stem cell population and they can also 
differentiate to form various specialised cells in an asymmetric division. In fact, they can arise from mutations in normal 
stem cells, progenitor cells or differentiated cells, and they are responsible for tumour formation and growth. For this 
reason, CSC directed therapies would lead to tumour regression, whereas conventional therapies cause tumour relapse. 
Cellular retinoic acid binding protein 2 (CRABP2); fatty acid binding protein 
5 (FABP5); peroxisome proliferator-activated receptor (PPAR); response 
element (RE); retinoic acid receptor (RAR); retinoid X receptor (RXR) 
Molecules in Figure 2 are from: Stem Cell Technologies. Technical Bulletin - Identification of viable stem and 
progenitor cells with Aldefluor [Online]. France; 2009. [Consultation 7/4/2016]. Available in: 
https://www.stemcell.com/~/media/Technical%20Resources/0/0/28728_aldefluor_July%202009.pdf?la=en 
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ALDH is not only a marker for cancer stem cells, and further studies are needed  
to resolve more questions about cancer 
